Medtech VCs Find Ways To Fill The Gaps
Executive Summary
The medtech venture capital ecosystem has certainly felt some strain lately as market pressures tighten the spigot for venture funding. At the IN3 meeting in October, members of a panel of medtech investors – three institutional and one corporate VC, and an entrepreneur – explained how they’re committing their capital during these difficult times.
You may also be interested in...
Late-Stage Venture Continues To Dominate Medtech Financing
Device start-ups raised $1.7 billion in 2013, and approximately 75% of the total was from Series C or later rounds, a sign that investors are still more comfortable making investments in more advanced companies.
Attack Of The Hair Restoration Robot
Robots invaded the operating room years ago, providing surgeons with high precision tools to perform a wide range of procedures from prostatectomies to partial knee replacements. Now, Restoration Robotics is hoping to take over the private practices of hair restoration surgeons. Last year, the venture-backed company launched ARTAS, a robotic system capable of minimally invasive removal of hair follicles used in hair transplants. Restoration Robotics executives see ARTAS as a way to level the playing field between hair restoration surgeons who are capable of performing the sometimes tricky follicular unit extraction and those who want to offer the procedure but don’t have the skills or resources. By conservative estimates, FUE accounts for less than 20% of the $1 billion hair restoration industry. Restoration Robotics sees its robotic system enabling more surgeons to perform FUEs, which could convince more prospective patients to undergo a hair restoration procedure.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”